Table 1 Baseline characteristics of patients included in the study
Characteristics | Total patients (n = 246) | Included patients (n = 180) | Included patients BMI ≤ 25 (n = 78) | Included patients BMI > 25 (n = 102) |
|---|---|---|---|---|
Age (years) | 47.6 ± 13.1 | 47.0 ± 12.7 | 42.9 ± 11.7 | 50.1 ± 12.6*** |
Male | 146 (59) | 107 (59) | 39 (50) | 68 (67)* |
Disease duration (years) | 10 (5–16) | 8 (5–16) | 7 (3–13) | 9 (6–18)** |
SpA subtype | ||||
Ankylosing spondylitis | 179 (78) | 140 (78) | 64 (82) | 76 (74) |
Non-radiographic SpA | 49 (22) | 40 (22) | 14 (18) | 26 (26) |
HLA-B27 | 174 (74) | 131 (73) | 61 (78) | 70 (69) |
Psoriasis/IBD/uveitis | 71 (29) | 58 (32) | 27 (35) | 31 (30) |
Peripheral arthritis | 97 (40) | 86 (48) | 38 (49) | 48 (47) |
BASDAI | 5.8 ± 2.0 | 5.8 ± 2.0 | 5.5 ± 2.1 | 6.0 ± 1.9 |
ASDAS | 3.3 ± 0.9 | 3.3 ± 1.0 | 3.2 ± 1.0 | 3.4 ± 1.0 |
ESR (mmHg) | 17 (7–33) | 17 (7–31) | 19 (6–34) | 16 (7–31) |
CRP (mg/L) | 5 (2–15) | 6 (3–17) | 7 (2–20) | 5 (3–15) |
Previous TNFi | 43 (18) | 35 (19) | 13 (17) | 22 (21) |
TNFi type | ||||
Infliximab | 107 (43) | 74 (41) | 25 (32) | 49 (48)* |
Adalimumab | 139 (57) | 106 (59) | 53 (68) | 53 (52)* |
csDMARD | ||||
Any csDMARD | 102 (42) | 79 (44) | 31 (40) | 48 (47) |
MTX | 34 (15) | 25 (14) | 12 (15) | 13 (13) |
SSZ | 46 (21) | 36 (20) | 10 (13) | 26 (25)* |
MTX and SSZ | 22 (9) | 18 (10) | 9 (11) | 9 (9) |
Prednisone | 22 (9) | 20 (11) | 11 (14) | 9 (9) |